We are live on ! Find out more
ONXX

ONYX PHARMACEUTICALS INC
ONXX

Delisted

ONXX was delisted on the 30th of September, 2013.

258 hedge funds and large institutions have $7.38B invested in ONYX PHARMACEUTICALS INC in 2013 Q3 according to their latest regulatory filings, with 83 funds opening new positions, 54 increasing their positions, 104 reducing their positions, and 95 closing their positions.

New
Increased
Maintained
Reduced
Closed

283% more funds holding in top 10

Funds holding in top 10: 1246 (+34)

55% more call options, than puts

Call options by funds: $1.26B | Put options by funds: $810M

5% less funds holding

Funds holding: 272258 (-14)

13% less first-time investments, than exits

New positions opened: 83 | Existing positions closed: 95

20% less capital invested

Capital invested by funds: $9.18B → $7.38B (-$1.8B)

48% less repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 104

Holders
258
Holders Change
-14
Holders Change %
-5.15%
% of All Funds
8.36%
Holding in Top 10
46
Holding in Top 10 Change
+34
Holding in Top 10 Change %
+283.33%
% of All Funds
1.49%
New
83
Increased
54
Reduced
104
Closed
95
Calls
$1.26B
Puts
$810M
Net Calls
+$448M
Net Calls Change
+$468M
Name Holding Trade Value Shares
Change
Change in
Stake
WIC
26
Water Island Capital
New York
$71.2M +$72.4M +571,429 New
PA
27
Perceptive Advisors
New York
$69.5M +$70.5M +556,944 New
PSAMP
28
P. Schoenfeld Asset Management (PSAM)
New York
$68.6M +$69.6M +550,000 New
MP
29
Manikay Partners
New York
$65.5M +$66.5M +525,000 New
LM
30
Litespeed Management
New York
$65.3M +$66.3M +523,368 New
TAL
31
TIG Advisors LLC
New York
$63.8M +$64.8M +511,752 New
UOC
32
UBS O'Connor
Illinois
$60.5M +$56.3M +444,886 +1,112%
JP Morgan Chase
33
JP Morgan Chase
New York
$60.1M -$736M -5,813,966 -92%
MG
34
Meditor Group
Bermuda
$54.2M -$66.7M -527,103 -55%
UBS AM
35
UBS AM
Illinois
$53.4M -$8.54M -67,458 -14%
HMC
36
Harvard Management Company
Massachusetts
$50.5M +$51.3M +405,000 New
Jennison Associates
37
Jennison Associates
New York
$48.1M -$129M -1,017,711 -72%
BG
38
BlackRock Group
United Kingdom
$46.3M -$10.3M -81,367 -18%
AQR Capital Management
39
AQR Capital Management
Connecticut
$45.6M +$44.7M +352,752 +2,671%
Bank of New York Mellon
40
Bank of New York Mellon
New York
$45.6M -$104M -823,399 -69%
T. Rowe Price Associates
41
T. Rowe Price Associates
Maryland
$44.1M -$580M -4,584,044 -93%
CC
42
Carlson Capital
Texas
$43M +$43.7M +345,000 New
PAI
43
Palo Alto Investors
California
$42.8M -$124M -981,642 -74%
AAA
44
Alpine Associates Advisors
New Jersey
$42.8M +$43.4M +343,100 New
Geode Capital Management
45
Geode Capital Management
Massachusetts
$42.4M +$5.57M +43,977 +15%
BB
46
BB Biotech
Switzerland
$42.4M -$26.2M -206,630 -38%
Deutsche Bank
47
Deutsche Bank
Germany
$41.2M -$50M -394,937 -54%
GCIA
48
Gabelli & Co Investment Advisers
New York
$38.1M +$38.6M +305,170 New
AIM
49
Allen Investment Management
New York
$37.6M +$38.2M +302,000 New
GIM
50
Granahan Investment Management
Massachusetts
$37.5M -$29.4M -232,000 -44%

ONXX Hedge Fund Activity: Q3 2013 in Review

258 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in ONYX PHARMACEUTICALS INC (ONXX) for Q3 2013, worth a combined $7.38B — down 20% from $9.18B a quarter earlier.

Sellers outnumbered buyers: 95 funds closed out of ONXX and 83 opened new positions — a net loss of 12 holders — while 104 trimmed existing stakes and 54 added.

The largest buyer was Davidson Kempner Capital Management, opening a new position worth an estimated $399M. The largest seller was BNP Paribas Financial Markets, cutting an estimated $1.39B.

  • 258 institutional investors held ONYX PHARMACEUTICALS INC (ONXX) as of Q3 2013, down from 272 in Q2 2013.
  • Funds reported $7.38B of ONYX PHARMACEUTICALS INC stock for Q3 2013, down 20% quarter-over-quarter.
  • 83 funds opened new ONYX PHARMACEUTICALS INC positions in Q3 2013 and 95 closed out, a net change of -12 holders.
  • The largest ONYX PHARMACEUTICALS INC buyer in Q3 2013 was Davidson Kempner Capital Management, an estimated $399M added.
  • The largest ONYX PHARMACEUTICALS INC seller in Q3 2013 was BNP Paribas Financial Markets, an estimated $1.39B sold.

Based on aggregated 13F filings for Q3 2013.